Are Iboga and Ibogaine Legal in Canada?
Iboga and Ibogaine are legal for personal use and possession in Canada. Though sale, distribution, and other activities involving the substance are illegal under Canadian federal law.
Ibogaine is a regulated prescription drug listed under Canada’s Prescription Drug List, though, according to Health Canada, it is not authorized for medical use. Its legal status outside this context is not well defined. Possession is not criminally prohibited, but the sale of health products containing ibogaine is prohibited.
Health practitioners can request ibogaine for patient use through Health Canada’s Special Access Program, though Health Canada is reportedly not inclined to grant such requests, on the grounds that insufficient clinical data exists to recommend its medical use.
What are Iboga and Ibogaine?
Iboga is a West African shrub historically used for ceremonial purposes by the Bwiti tribe of West Africa. Ibogaine is the active psychoactive alkaloid contained in its root bark. The bark can be consumed in ground-up form, or ibogaine extract can be consumed in semi-synthetic form. Its psychoactive effects can last up to 24 hours depending on dosage.
The experience of ibogaine is reportedly extremely intense and not pleasant. Some regard it as the most powerful psychedelic. Anecdotally, users report that one may view one’s entire life as if watching a movie, detached from the subject.
Those looking to learn more about ibogaine can read a Substack post we wrote about the subject. The Rich Roll Podcast also has a good episode describing the experience of iboga in detail.
Medical or Therapeutic Use?
Studies suggest that ibogaine used under proper conditions may be helpful in treating addiction and PTSD-related depression and anxiety. However, ibogaine use remains controversial (even by the standard of other psychedelics) due to its high toxicity and potential cardiac risk, especially if used improperly.
In 2025, the State of Texas passed a law to fund research focusing on the use of ibogaine for “neurological and mental health conditions.” The state’s government was motivated to passed the law on account ibogaine’s “great promise” in treating psychological issues affecting military veterans specifically.
A Common Misconception
Some online sources, particularly international treatment and/or retreat websites, incorrectly claim that ibogaine is a “Schedule I” controlled substance in Canada. It is not. Ibogaine is not listed under any schedule of the Controlled Drugs and Substances Act. It is instead regulated as a prescription drug on Health Canada's Prescription Drug List. Personal possession is not criminally prohibited, but selling or distributing health products containing ibogaine is prohibited, and ibogaine is not authorized for medical use in Canada. Readers relying on inaccurate scheduling claims risk misunderstanding both their legal exposure and their options.
International Momentum: The Texas Ibogaine Initiative
While ibogaine remains unavailable for medical use in Canada, the United States has become the centre of a fast-moving research push. In 2025, Texas enacted Senate Bill 2308 and committed US$50 million to fund clinical trials aimed at securing FDA approval of ibogaine for opioid use disorder, PTSD, and traumatic brain injury the largest government investment in psychedelic research to date.
The program was originally designed as a public-private partnership requiring a private developer to match the state's funding. No qualifying partner materialized, and on March 31, 2026, Texas leadership announced the state would proceed on its own through in-state institutions. The US$50 million was awarded to UTHealth Houston with the University of Texas Medical Branch at Galveston to co-lead a two-year multicentre trial known as IMPACT (Ibogaine Medicine for PTSD, Addiction, and Cognitive Trauma).
The model is beginning to spread: in March 2026, Mississippi and West Virginia advanced legislation to join the effort. For Canadians, the Texas program is worth watching because FDA approval would reshape the international regulatory conversation, and could increase pressure on Health Canada to reconsider its current reluctance to authorize ibogaine through the Special Access Program.
Federal signal: the April 2026 executive order
The momentum reached the federal level in April 2026. On April 18, President Trump signed Executive Order 14401, directing the FDA to accelerate review of psychedelic treatments and dedicating $50 million in federal research funding. Notably, ibogaine was the only substance named in the order, a striking distinction given that better-studied psychedelics such as psilocybin and MDMA went unnamed. Following the signing, the FDA Commissioner indicated that ibogaine could move toward approval once the agency reviews data from late-stage clinical trials. Commentators have cautioned that the order's near-term impact is largely symbolic, as ibogaine remains a Schedule I substance under U.S. federal law and any FDA approval would still depend on the outcome of clinical trials.
Frequently Asked Questions
-
Iboga and ibogaine are legal for personal use and possession in Canada, as ibogaine is not listed under the Controlled Drugs and Substances Act. However, ibogaine is on Health Canada's Prescription Drug List and is not authorized for medical use, and the sale and distribution of health products containing ibogaine is prohibited.
-
No. Despite claims to the contrary in some online sources, ibogaine is not scheduled under Canada's Controlled Drugs and Substances Act. It is instead regulated as a prescription drug under the Food and Drugs Act framework, which prohibits unauthorized sale but not personal possession.
-
Health practitioners can request ibogaine for patient use through Health Canada's Special Access Program, though to our knowledge, no approvals have been granted.
Reviewed by Marc Z. Goldgrub, Founding Lawyer, Green Economy Law Professional Corporation (Law Society of Ontario; New York State Bar) · Last updated: 2026-05-08
Stay updated on the firm’s work and psychedelic law developments in Canada and elsewhere.